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Abstract
Mechanical ventilation is the cornerstone of therapy for patients
with acute respiratory distress syndrome (ARDS). Paradoxically,
mechanical ventilation can exacerbate lung damage – a phenomenon
known as ventilator-induced lung injury. While new ventilation
strategies have reduced the mortality rate in patients with ARDS,
this mortality rate still remains high. High-frequency oscillatory
ventilation (HFOV) is an unconventional form of ventilation that may
improve oxygenation in patients with ARDS, while limiting further
lung injury associated with high ventilatory pressures and volumes
delivered during conventional ventilation. HFOV has been used for
almost two decades in the neonatal population, but there is more
limited experience with HFOV in the adult population. In adults, the
majority of the published literature is in the form of small
observational studies in which HFOV was used as ‘rescue’ therapy
for patients with very severe ARDS who were failing conventional
ventilation. Two prospective randomized controlled trials, however,
while showing no mortality benefit, have suggested that HFOV,
compared with conventional ventilation, is a safe and effective
ventilation strategy for adults with ARDS. Several studies suggest
that HFOV may improve outcomes if used early in the course of
ARDS, or if used in certain populations. This review will summarize
the evidence supporting the use of HFOV in adults with ARDS.
Introduction
Mechanical ventilation remains the cornerstone of therapy for
patients with acute respiratory distress syndrome (ARDS)
and acute lung injury. Paradoxically, mechanical ventilation
has the potential to cause further lung injury in patients with
ARDS and acute lung injury – a phenomenon known as
ventilator-induced lung injury, which occurs when alveolar
overdistension due to high ventilator pressures or volumes
disrupts the alveolar epithelial membrane (volutrauma) [1].
Lung injury can also occur in the setting of repeated opening
and closing of alveoli due to inadequate end-expiratory
alveolar recruitment, which can disrupt both the alveolar
epithelial and capillary endothelial membranes (atelectrauma).
These mechanical insults lead to the release of inflammatory
cytokines that further exacerbate lung injury and may
contribute to the development of multiple organ failure [1-3].
Lung-protective conventional ventilation (CV) strategies are
structured to limit alveolar overdistension, with the use of
small tidal volumes and low end-inspiratory pressures, and to
avoid repeated end-expiratory alveolar collapse with
adequate positive end-expiratory pressure. Such a strategy
was evaluated in the ARDS Network trial, and was associated
with a 9% absolute reduction in mortality compared with a
strategy that employed a higher tidal volume [4]. Notwith-
standing, mortality in the low tidal volume group remained
high at 31%, spurring investigators to develop alternative
lung-protective mechanical ventilation strategies that could
further reduce mortality in patients with ARDS.
High-frequency oscillatory ventilation –
potential benefits and mechanisms
High-frequency oscillatory ventilation (HFOV) theoretically
satisfies all of the goals of a lung-protective strategy, and
offers several potential advantages over CV. Utilizing a
piston pump, HFOV achieves gas exchange by delivering
very small tidal volumes at frequencies ranging from 3 to
15 Hz. The potential advantages of HFOV over CV include:
the delivery of smaller tidal volumes, limiting alveolar over-
distension; the application of a higher mean airway pressure
(mPaw) than that in CV, promoting more alveolar recruit-
ment; and the maintenance of a constant mPaw during
inspiration and expiration, thus preventing end-expiratory
alveolar collapse.
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The principles of oxygenation during HFOV are similar to
those during CV, and oxygenation is dependent on an optimal
lung volume recruitment strategy (mPaw) and the consequent
reduction of intrapulmonary shunting of blood. Ventilation is
inversely related to the respiratory frequency and is directly
related to the excursion of the diaphragm, the latter
expressed as the pressure amplitude of oscillation. By main-
taining a continuous distending pressure, HFOV facilitates
CO2 elimination mainly by accelerating the molecular
diffusion processes. Gas transport and CO2 elimination
during HFOV, however, also result from several other
mechanisms, including bulk convection, pendelluft, Taylor
dispersion, and cardiogenic mixing [5].
During HFOV a piston pump oscillates at frequencies
between 180 and 1800 breaths/min. As the ventilator itself is
a closed system and does not provide fresh gas, a bias flow
of gas at 5–60 l/min is used across the tubing connecting the
oscillator to the patient. The amount of bias flow, together
with a resistance valve in the circuit, is used to control the
mPaw within the circuit. HFOV is unique, compared with
other modes of high-frequency ventilation, because the return
stroke of the piston during expiration creates a vacuum,
leading to active expiration of gas. Humidification in HFOV is
easily achieved by passing the bias flow of gas through a
humidifier.
In some animal models, the use of HFOV is associated with
less evidence of lung injury, as demonstrated by reduced
lung expression of inflammatory cytokines – including IL-1β,
IL-6, IL-8, IL-10, transforming growth factor and adhesion
molecules, as well as messenger RNA for TNF – compared
with CV [6-8]. These cytokine reductions were noted despite
the application of similar mPaw during HFOV and CV. One
study in neonates demonstrated cytokine reductions during
HFOV [9], while two other human studies have shown
negative results [10,11]. Animal models also demonstrate
reduced pathological injury with HFOV, with less hyaline
membrane formation, less alveolar leukocyte infiltration and
less airway epithelial damage compared with CV [12-14]. In a
rabbit model, HFOV was associated with a reduction in TNF
levels, leukocyte infiltration and pathological changes even
when compared with a CV strategy that emphasized low tidal
volume and high positive end-expiratory pressure [15]. In
contrast, the use of HFOV in premature neonates did not
reduce concentrations of albumin, IL-8 and leukotriene B4,
when compared with high-rate, low-pressure CV [16].
The applied mPaw during HFOV is usually higher than that
applied during CV [17,18]. Theoretically, a higher sustained
mPaw increases alveolar recruitment, which improves
ventilation–perfusion matching and oxygenation. This was
demonstrated in a study using electrical impedance
tomography, in which HFOV resulted in a homogeneous lung
volume distribution compared with nonuniform lung inflation
during the inflation limb of a pressure–volume curve
manoeuvre [19]. The high mPaw applied during HFOV is not
associated with high peak airway pressures, as the pressure
oscillations produced by the piston are significantly
attenuated distally, resulting in low-amplitude alveolar pressure
oscillations around the mPaw. The use of HFOV therefore
allows the application of a higher overall mPaw without
abandoning a ‘lung-protective’ strategy.
The active expiratory phase is a unique feature of HFOV, and
may be important for alveolar ventilation. At typical HFOV
settings, bulk flow appears to play a minor role in ventilation,
given that the tidal volume at typical ventilator settings is
approximately 2 ml/kg [20], which is lower than anatomical
dead space. Bulk flow, however, probably occurs at lower
frequencies and higher pressure amplitudes, which result in
tidal volumes closer to the CV range [21]. Other proposed
mechanisms of ventilation during HFOV include asymmetric
velocity profiles, pendelluft, cardiogenic mixing, laminar flow
with Taylor dispersion, collateral ventilation and molecular
diffusion [5,22].
Clinical trials
A large number of randomized controlled trials in the neonatal
literature have failed to show a mortality benefit associated
with the use of HFOV. The number of trials evaluating HFOV
in adults is more modest, with only two randomized controlled
trials [23,24] and a handful of case series. Most of the
studies have used HFOV as ‘rescue’ therapy for patients with
severe ARDS who are failing CV. Table 1 presents a
summary of these trials. None of these trials have shown a
reduction in mortality with the use of HFOV.
In the first published observational study, Fort and colleagues
reported their experience with HFOV in 17 patients with
ARDS due to sepsis or pneumonia [17]. The severity of
illness was high, with a mean Acute Physiologic and Chronic
Health Evaluation (APACHE) II score of 23.3 and an
oxygenation index (OI) – (Paw × FiO2 × 100) / PaO2 – of
48.6. Patients had significant improvements in the FiO2 and
OI over the 48-hour study duration, and the 30-day mortality
rate was 53%. Of note, nonsurvivors had a higher baseline OI
and had been ventilated conventionally for more days prior to
HFOV than survivors.
Four subsequent observational studies were similar in a
number of important details [18,25-27]. In these studies, the
number of patients was small, ranging from 16 to 42, and
most patients had ARDS secondary to sepsis or pneumonia.
In all cases, HFOV was used as rescue therapy for patients
with severe ARDS who remained hypoxaemic during CV. In
all four of these studies the initiation of HFOV was associated
with significant improvements in oxygenation within 24 hours.
Mortality rates in these studies were high, but the patients
were very ill (mean APACHE II score >21, PaO2/FiO2 =
73–98 mmHg), and the majority of deaths occurred due to
multiorgan failure. As in the study by Fort and colleaguesPage 3 of 8
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[17], Mehta and colleagues [18] also observed that
nonsurvivors were ventilated conventionally for a longer
duration prior to HFOV than survivors, suggesting that early
application of HFOV may be advantageous.
In one study of 42 patients with ARDS, David and colleagues
observed a higher mortality rate in patients who failed to
improve their oxygenation in response to HFOV (change in
PaO2/FiO2 <50), compared with patients who responded
[26]. Furthermore, the mortality rate in patients ventilated
conventionally for ≥3 days prior to HFOV was 64%, compared
with 20% mortality in patients ventilated conventionally for
<3 days.
The largest observational study was published by Mehta and
colleagues, who reported their experience with 156 patients
Available online http://ccforum.com/content/10/6/240
Table 1
Studies evaluating the use of high-frequency oscillatory ventilation in adult patients with acute respiratory distress syndrome
Mean CV  Death due 
Study  Baseline  prior to  to respiratory 
Author, year design n characteristics HFOV (days) Mortality failure (%) Selected complications
Fort and  Prospective,  17 Mean age 38, APACHE II  5.1 30-day mortality  33 3 (17.6%) HFOV 
colleagues,  observational score 23, PaO2/FiO2 53% patients withdrawn for 
1997 [17] ratio 69, OI 49 hypotension
Claridge and  Prospective,  5 Trauma patients; mean  1.4 20% 0 None reported
colleagues,  observational age 37, APACHE II score 
1999 [30] 28, PaO2/FiO2 ratio 52
Mehta and  Prospective,  24 Mean age 48, APACHE II  5.7 30-day mortality  6 2 patients (8.3%) had 
colleagues,  observational score 22, PaO2/FiO2 66% pneumothorax
2001 [18] ratio 99, OI 32
Derdak and  Randomized  148 Mean age 50, APACHE II  2.8 30-day mortality:  16 in  Similar in both groups
colleagues,  controlled trial score 22, PaO2/FiO2 HFOV 37%,  both 
2002 [23] ratio 112, OI 25 CV 52% arms
Andersen and  Retrospective 16 Mean age 38, SAPS II  7.2 3-month mortality  Not  1 (6.3%) patient had 
colleagues,  score 40, PaO2/FiO2 31% reported pneumothorax
2002 [25] ratio 92, OI 28
David and  Prospective,  42 Median age 49, APACHE II  3.0 30-day mortality  33 1 (2.4%) patient had 
colleagues,  observational score 28, PaO2/FiO2 43% pneumothorax
2003 [26] ratio 94, OI 23
Cartotto and  Retrospective 25 Burn patients; mean  4.8 Inhospital  4 3 (12%) patients had 
colleagues,  age 44, APACHE II  mortality 32% severe hypercapnea
2004 [29] score 17
Mehta and  Retrospective 156 Median age 48, APACHE II  5.6 30-day mortality  Not  34 (21.8%) patients had 
colleagues,  score 24, PaO2/FiO2 62% reported pneumothorax
2004 [28] ratio 91, OI 31
Bollen and  Randomized  61 Mean age 81, APACHE II  2.1 HFOV 43%,  0 in  HFOV: 4 (10.8%) 
colleagues,  controlled trial score 21, HFOV 37 patients,  CV 33% both arms patients had 
2005 [24] CV 24 patients, OI 22 hypotension, 1 (2.7%) 
patient had air leak; CV: 
1 (4.2%) patient had 
hypotension, 1 (4.2%) 
patient had air leak
Ferguson and  Prospective 25 Mean age 50, APACHE II  0.5 44% in intensive  Not  5 (25%) patients had 
colleagues,  score 24, PaO2/FiO2 care unit assessed barotrauma
2005 [42] ratio 121, OI 23
Pachl and  Prospective,  30 Mean age 55, SOFA  7.7 46.7% Not  Not reported 
colleagues,  observational score 9.6, PaO2/FiO2 reported
2006 [20] ratio 121, OI 26
Finkielman and  Retrospective 14 Mean age 56, APACHE II  1.7 30-day mortality  Not  1 patient had HFOV 
colleagues,  score 35, PaO2/FiO2 57% reported discontinued for 
2006 [27] ratio 73, OI 35 haemodynamic instability
APACHE, Acute Physiology and Chronic Health Evaluation; CV, conventional ventilation; OI, oxygenation index (FiO2 × mean airway pressure ×
100 / PaO2); HFOV, high-frequency oscillatory ventilation; SAPS, Simplified Acute Physiology Score; SOFA, sequential organ failure assessment.with severe ARDS at three academic hospitals [28]. HFOV
was used as rescue therapy for patients failing CV, and the
severity of illness and mortality rates were quite high (mean
APACHE II score = 24, OI = 31, mortality = 61.7%). The
authors reported a high rate of pneumothoraces (22%), and
26% of patients had HFOV discontinued because of
difficulties with oxygenation, ventilation or haemodynamics.
Predictors of poor outcome on multivariable analysis were
older age, higher APACHE II score, lower pH and a greater
number of CV days prior to HFOV. The most significant post-
treatment predictor of mortality was the OI at 24 hours.
Two studies evaluated HFOV in very specific patient
populations. Cartotto and colleagues reported significant
improvements in oxygenation within 1 hour of initiating HFOV
in 25 patients admitted to a specialized burn unit [29]. In
trauma patients, Claridge and colleagues reported a signifi-
cant and persistent improvement in oxygenation within
2 hours of initiation of HFOV [30].
Only two prospective, randomized controlled trials have
compared HFOV with CV in adults, involving a total of 209
patients. The first trial enrolled 148 patients to evaluate the
safety and efficacy of HFOV compared with CV [23]. They
observed an early but nonsustained improvement in the
PaO2/FiO2 ratio in the HFOV group compared with the
control group, with similar complication rates in both groups.
Although the trial was not powered to detect a mortality
difference, there was a nonsignificant trend towards reduced
30-day mortality (37% versus 52%, P = 0.102) in the HFOV
group, which persisted at 90 days. This study has been
criticized because the CV group received a higher tidal
volume (8 ml/kg measured body weight, 10.6 ml/kg predicted
body weight) and peak airway pressures (38 ± 9 cmH2O at
48 hours) than are currently considered the standard of care
following the publication of the ARDS Network trial results
[4]. This trial, however, was designed prior to the publication
of the ARDS Network trial.
The other randomized controlled trial was terminated
prematurely after enrolment of 61 patients with ARDS, due to
poor accrual. Bollen and colleagues found an early improve-
ment in the OI in patients treated with HFOV, but no differen-
ces in mortality or failure of therapy between the HFOV and
CV groups [24]. The results of this trial are difficult to
interpret because of the small number of patients, as well as
the baseline differences between the HFOV and CV groups
in the OI (25 versus 18) and the PaO2 (81 mmHg versus
93 mmHg), a lack of explicit ventilation protocols and an 18%
crossover rate to the alternate arm.
The relative success of HFOV depends on the control
ventilation strategy with which it is compared. Future ran-
domized trials of HFOV in adults with ARDS will require
thoughtful design of the conventional control strategy, consis-
tent with the current lung-protective standard of care. Several
animal studies [14,31,32] show comparable physiological
responses from HFOV and conventional mechanical
ventilation when similar strategies are used for ventilation.
There may therefore be no difference in outcome if both
HFOV and CV are applied with a similar open lung-protective
strategy.
In summary, a small number of studies show that the use of
HFOV in adult patients with ARDS is associated with
improvements in oxygenation, without a significant reduction
in mortality. Application of HFOV early in the course of ARDS
may be associated with improved outcomes. A recent
Cochrane review that included one adult trial and one
paediatric trial concluded that there was not enough
evidence to demonstrate a morbidity or mortality benefit of
HFOV over CV [33].
Haemodynamic effects of HFOV
Theoretically, haemodynamic compromise may occur during
HFOV due to the higher mPaw, the consequent higher
pleural pressure and the reductions in venous return and
cardiac output. In a large observational study by Mehta and
colleagues, 32 patients (20.5%) had a pulmonary artery
catheter in place during HFOV [28]. Patients treated with
HFOV had an early and nonpersistent increase in pulmonary
artery occlusion pressure (PAOP), a small persistent increase
in central venous pressure and a small decrease in cardiac
output compared with baseline, associated with a mPaw
increase of 8 cmH2O. These findings are very similar to three
previous clinical studies in adults reporting an early rise in
central venous pressure and/or PAOP [17,18,26], and two
other studies reporting a reduction in cardiac output with the
application of HFOV [28,34]. Two paediatric studies also
found significant reductions in cardiac output measured
noninvasively in infants converted from CV to HFOV [35,36].
In contrast, the randomized trial by Derdak and colleagues
found no significant differences in the heart rate, mean arterial
blood pressure or cardiac output between HFOV and CV
groups over the initial 72 hours of treatment [23]. Pulmonary
artery catheters were present in 56% (42/75) of HFOV
patients and in 51% (37/73) of CV patients. The PAOP was
slightly higher in the HFOV group compared with the CV
group throughout the initial 72 hours (P = 0.008), and the
central venous pressure and PAOP were significantly
increased at 2 hours compared with baseline values.
The clinical significance of these haemodynamic effects is not
known, as none of the studies have reported fluid or
vasopressor administration at the time of HFOV initiation. A
recent animal study [31] compared the impact of lung
recruitment (up to 30 cmH2O) on the haemodynamics and
organ blood flow during HFOV and CV. Regardless of the
ventilatory approach, at comparable mPaw the blood flow to
the brain, kidneys and jejunum was maintained during
recruitment. Organ perfusion was maintained despite
Critical Care    Vol 10 No 6 Downar and Mehta
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and stroke volume, and increases in the left ventricular end-
diastolic pressure, PAOP and intracranial pressure during
both HFOV and CV.
Predictors of response to HFOV
One possible explanation for the lack of mortality benefit of
HFOV is that the intervention is introduced too late in the
course of ARDS. Three prospective trials and one retro-
spective trial identified the duration of CV prior to the
initiation of HFOV as an independent predictor of mortality
[17,18,26,28]. In addition, a recent systematic review found
that the duration of CV prior to starting HFOV differed
significantly between survivors and nonsurvivors [37]. When
adjusted for age and the APACHE II score, each extra day on
CV prior to starting HFOV was associated with a 20% higher
mortality, although this association disappeared when pH
was included in the multivariate analysis. The authors
concluded that prolonged CV prior to HFOV was not related
to mortality.
Although HFOV has not been shown to reduce mortality in
patients with ARDS, there may be certain subgroups who
benefit. Although Bollen and colleagues reported no mortality
difference between the HFOV-treated and CV-treated
groups, a post-hoc multivariate analysis, which included
adjustment for the APACHE II score and age, showed that
patients with a higher baseline OI had a lower odds ratio for
mortality when treated with HFOV compared with CV [24].
This effect achieved statistical significance for patients with
an OI >30.
Pachl and colleagues compared the effects of HFOV in 30
patients with ARDS due to pulmonary causes (for example,
pneumonia, lung contusion) or extrapulmonary causes (for
example, sepsis, pancreatitis) [20]. With the application of a
similar HFOV strategy in these two groups, patients with
extrapulmonary ARDS showed significant improvements in
the PaO2/FiO2 ratio with HFOV, whereas patients with
pulmonary ARDS showed no improvement. This may be due
to more recruitable lung tissue present in patients with
extrapulmonary ARDS, as shown by Gattinoni and colleagues
during CV [38]. The poor response of patients with pulmo-
nary ARDS, however, may have been due to a significantly
longer duration of CV prior to HFOV than that for patients
with extrapulmonary ARDS (10.7 days versus 4.95 days,
P = 0.017). Indeed, patients whose PaO2/FiO2 ratio improved
during HFOV had a shorter duration of pretreatment with CV,
and a higher baseline OI than nonresponders.
HFOV and adjunctive therapies
HFOV has been studied in conjunction with inhaled nitric
oxide, recruitment manoeuvres (RMs) and prone positioning
to further improve oxygenation. Mehta and colleagues
administered inhaled nitric oxide at 5–20 ppm to patients
receiving HFOV and found that 91% of patients
demonstrated at least a 20% improvement in the PaO2/FiO2
ratio, with an average improvement in the PaO2/FiO2 ratio of
37% [39]. The use of inhaled nitric oxide allowed significant
reductions in FiO2 within 8–12 hours of initiation. Mehta and
colleagues postulated that alveolar recruitment during HFOV
may increase the amount of the alveolar/capillary interface
available for inhaled nitric oxide to act upon, potentially
resulting in greater improvements in ventilation–perfusion
matching than with each individual therapy.
Lung recruitment can take up to 12 hours with HFOV due to
the low tidal volumes and the lack of ‘tidal recruitment’
[40,41]. The use of RMs may increase or hasten alveolar
recruitment. Ferguson and colleagues evaluated the regular
use of RMs in 25 adults with early ARDS [42]. They applied a
series of three RMs (mPaw 40 cmH2O for 40 s) at HFOV
initiation, twice daily, and as needed for hypoxaemia. This
strategy resulted in a significant and sustained improvement
in oxygenation, which occurred more rapidly than reported in
other HFOV studies [17,18,23]. Of note, oxygenation improve-
ments associated with the RMs were greater during the initial
days of HFOV. Only eight out of 244 (3.3%) RMs were
aborted, mainly for transient hypotension.
Papazian and colleagues compared the impact of supine
HFOV, prone HFOV and prone CV on 12-hour oxygenation in
39 patients with ARDS [11]. While both groups of prone
patients (CV and HFOV) had similar and significant improve-
ments in oxygenation, the supine HFOV group showed no
improvement. These data are in contrast to previously
published studies showing improvements in oxygenation
following the initiation of HFOV [17,18,23,28]. The most
probable explanation for this difference is that an insufficient
airway pressure was applied during HFOV in Papazian and
colleagues’ study. The average mPaw applied was only
25 cmH2O, compared with >30 cmH2O in previous studies
[17,18,23,28]. The improvement in oxygenation in the prone
HFOV group therefore probably reflects the effect of the
change in position only, and not the combined effect of the
two modalities. Furthermore, the 12-hour observation period
may have been insufficient for maximal HFOV-induced lung
recruitment, as other studies have shown that the maximal
improvement in oxygenation occurs beyond 12 hours [17,23].
Strategies such as nitric oxide, prone positioning and RMs
may further improve oxygenation in patients with ARDS who
are being treated with HFOV, although there have been no
demonstrated mortality benefits with any of these adjunctive
therapies.
Predictors of mortality on HFOV
Many observational studies of HFOV have found a correlation
between mortality and the APACHE II score, the OI or the
duration of pretreatment with CV. In their large retrospective
study, Mehta and colleagues found that independent
predictors of mortality at baseline included age, the APACHE
Available online http://ccforum.com/content/10/6/240
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HFOV [28]. In addition, they reported that the most signifi-
cant post-treatment predictor of mortality was the OI at
24 hours. This association was also observed by Derdak and
colleagues, who found the 16-hour OI to be the most
significant post-treatment predictor of outcome [23]. On the
other hand, Bollen and colleagues found that the degree of
early post-treatment improvement in OI was not associated
with mortality [24].
Bollen and colleagues performed a systematic review of
predictors of mortality in patients treated with HFOV [37]. In
their analysis of nine trials (two randomized and seven
observational), they found that survivors and nonsurvivors
differed significantly in terms of age, prior time on CV,
APACHE II score, pH and OI. On multivariate analysis,
however, only the OI was found to be independently
associated with mortality.
When and how to initiate HFOV, and
challenges in management of patients on
HFOV
Any patient with ARDS who remains hypoxaemic during CV
can be considered for HFOV. ARDS is defined as the
presence of bilateral infiltrates on chest radiograph, a
PaO2/FiO2 ratio <200 mmHg and no clinical evidence of left
ventricular failure. HFOV is not indicated for pure hyper-
capneic, nonhypoxaemic respiratory failure. In our intensive
care unit we consider HFOV when patients require a FiO2
>0.6 and a positive end-expiratory pressure >10 cmH2O, or
peak inspiratory pressures >35 cmH2O. Suggested initiation
settings for HFOV are presented in Table 2. Detailed
management strategies for HFOV are beyond the scope of
the present review, and have been summarized elsewhere
[23,42,43].
Ventilation during HFOV should ideally occur in the ‘safe
zone’ of the pressure–volume curve, avoiding both end-
expiratory derecruitment and inspiratory overdistension. How-
ever, clinical assessment of optimal lung recruitment during
HFOV is challenging. We currently use chest radiography
and gas exchange to assess recruitment. Luecke and
colleagues demonstrated in an animal model that volumes
measured by computed tomography during HFOV were
equal to those predicted from static pressure–volume curves
[44]. Brazelton and colleagues found that respiratory-induc-
tive plethysmography could be used to accurately determine
lung volumes during HFOV in an animal model [45], and
Tingay and colleagues successfully used respiratory-inductive
plethysmography to guide HFOV in neonates [46]. Unfortu-
nately, the use of respiratory-inductive plethysmography and
computed tomography are not practical in most intensive
dare units, and the latter carries with it the risks of trans-
portation. In clinical practice, to find the ‘safe zone’ during
HFOV, the mPaw can be titrated up the inflation limb (to
recruit) and down the deflation limb (to find the least pressure
required to keep the lung open) of the static pressure–
volume curve, using oxygenation as an outcome. This
technique may allow a substantial reduction in the mPaw
while reducing haemodynamic consequences [42,44].
Unlike neonates, adult patients generally require deep
sedation and neuromuscular blockade to tolerate HFOV. By
design, the 3100B ventilator (Viasys Healthcare Inc., Yorba
Linda, CA, USA) has inadequate bias flow to meet the
inspiratory demands of many spontaneously breathing adults
with ARDS, and a recent bench study showed that
spontaneous breathing during HFOV resulted in considerable
imposed work of breathing in adults [47]. Many patients with
ARDS therefore experience discomfort or dyspnea with
spontaneous inspiration during HFOV. They may generate
large negative airway pressures causing fluctuations in the
circuit mPaw. These fluctuations may be sensed by the
3100B ventilator as a circuit disconnection, which causes the
ventilator to shut off.
There are unique challenges in caring for patients on HFOV.
The continuous noise precludes cardiac and respiratory
auscultation. Continuous patient movement during HFOV
means that procedures such as central venous catheter
Critical Care    Vol 10 No 6 Downar and Mehta
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Table 2
Initial parameters for high-frequency oscillatory ventilation
Parameter Initiation settings
FiO2 Same FiO2 that patient was receiving during conventional ventilation, adjust to SpO2 > 90%
Mean airway pressure (mPaw) 3–5 cmH2O higher than patient was receiving during conventional ventilation, titrate upward 
to reduce FiO2 below 0.6
Bias flow 40 l/min, titrate to exceed any spontaneous inspiratory efforts
Pressure amplitude of oscillation (‘power’ or ∆P) Titrate to produce a ‘wiggle’, or body movement, from shoulders to midthigh
Frequency 5 Hz, then titrate to PaCO2
Percentage inspiratory time 33%insertion or bronchoscopy are challenging. Suctioning is
associated with alveolar derecruitment, especially with circuit
disconnection, so routine suctioning should be avoided. If the
patient requires transportation, there must be an adequate
battery transport system and a good supply of compressed
air and oxygen.
One of the most important potential advantages of HFOV
compared with CV relates to the delivery of small tidal
volumes. The tidal volume delivered during HFOV correlates
directly with the pressure amplitude, and correlates inversely
with the frequency. Neonates tolerate frequencies up to
15 Hz with adequate ventilation, whereas most studies in
adults have applied frequencies between 3 and 6 Hz, which
may be a cause for concern. At the low rates and high-
pressure amplitudes used in adults, Sedeek and colleagues
showed that tidal volumes approaching CV can be delivered
during HFOV [21]. In adults, therefore, clinicians should strive
to apply the highest frequencies possible, within the limits of
acceptable ventilation and pH.
HFOV is not effective in all patients. Of 156 patients treated
with HFOV, Mehta and colleagues reported that 26% had
HFOV discontinued due to difficulties with oxygenation,
ventilation or haemodynamics [28]. For hypotension related
to the higher intrathoracic pressures, cautious intravascular
volume loading may be required to maintain the venous return
and cardiac output during HFOV. The potential for baro-
trauma is a concern, given the high mPaw applied during
HFOV. The risk of pneumothorax varies in the published
studies, probably relating to differences in the patient
populations. While Mehta and colleagues reported an
incidence of 21.8% [28], most other HFOV studies found
rates below 10%, similar to non-HFOV ventilation studies in
the ARDS population (Table 1). In the two randomized
controlled trials comparing HFOV and CV, the rate of
pneumothorax or other air leak was similar in the two groups
[23,24], suggesting that the high incidence of pneumothorax
in the study by Mehta and colleagues was related to the
severity of disease rather than the ventilation strategy.
Conclusions and future directions
HFOV can be safely applied in adults with ARDS, and is
associated with initial improvements in oxygenation and
adequate ventilation, but without any mortality benefit. These
conclusions, however, are based on a small number of
studies, of which only two are randomized controlled trials.
Future studies should compare HFOV with an open lung-
protective strategy to determine whether one strategy is
superior, whether earlier initiation of HFOV might improve
outcomes and whether certain subgroups of patients may
derive greater benefit from HFOV.
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